Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis

J Am Coll Cardiol. 2011 Aug 23;58(9):935-41. doi: 10.1016/j.jacc.2011.05.022.

Abstract

Objectives: The purpose of this study was to perform a systematic review and meta-analysis of prospective randomized clinical trials of cardiac resynchronization therapy (CRT) versus implantable cardioverter-defibrillator (ICD) in patients with reduced ejection fraction (EF), prolonged QRS interval, and New York Heart Association (NYHA) functional class I to II heart failure (HF).

Background: In patients with advanced HF, CRT improves left ventricular (LV) function and reduces mortality and hospitalizations. Recent data suggest that patients with milder HF also benefit from CRT.

Methods: A meta-analysis of 5 clinical trials including 4,317 patients with NYHA functional class I/II HF was performed.

Results: Average age of patients was 65 years, and 80% were male. Frequency of all-cause mortality for CRT versus ICD was 8% versus 11.5% (risk ratio [RR]: 0.81; 95% confidence interval [CI]: 0.65 to 0.99, p = 0.04); for HF hospitalization, it was 11.6% versus 18.2% (RR: 0.68; 95% CI: 0.59 to 0.79, p < 0.001). Patients assigned to CRT had a significantly greater improvement in LVEF (+5.9% vs. +2.2%, p < 0.001) and LV volume than ICD patients. Among mildly symptomatic (NYHA functional class II) patients, CRT was associated with significantly lower mortality and HF hospitalization (RR: 0.73; 95% CI: 0.64 to 0.83), p < 0.001). In asymptomatic (NYHA functional class I) patients, HF hospitalization risk was lower (RR: 0.57; 95% CI: 0.34 to 0.97, p = 0.04) with CRT; however, there was no difference in mortality. Twelve asymptomatic HF patients needed to be treated with CRT to prevent 1 hospitalization.

Conclusions: Cardiac resynchronization therapy decreases all-cause mortality, reduces HF hospitalizations, and improves LVEF in NYHA functional class I/II HF patients. Although there was a reduction in HF hospitalization with CRT for asymptomatic (NYHA functional class I) patients, risks versus benefits have to be carefully considered in this subgroup.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Aged
  • Cardiac Resynchronization Therapy* / methods
  • Cardiac Resynchronization Therapy* / trends
  • Female
  • Heart Failure / diagnosis
  • Heart Failure / mortality*
  • Heart Failure / therapy*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Randomized Controlled Trials as Topic / methods*
  • Randomized Controlled Trials as Topic / trends